Safety and efficacy of intra-articular injections of platelet-rich plasma for the treatment of osteoarthritis of the knee in the Japanese population

Safety and efficacy of intra-articular injections of platelet-rich plasma for the treatment of osteoarthritis of the knee in the Japanese population - Safety of platelet-rich plasma for the treatment of osteoarthritis of the knee

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000011829

Enrollment

Registered

2013-10-01

Start date

2013-10-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Osteoarthritis of the knee

Interventions

Intra-articlar injections of platelet-rich plasma derived from autologous peripheral blood

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. With a history of chronic (for at least 3 months) knee joint pain more than 35-mm on 0- to 100-mm visual analogue scale 2. Radiographically documented grades 1-3 osteoarthritis of the knee, grade according to the Kellgren-Lawrence radiographic classification scale 3. BMI ranging between 20 and 32 4. Requiring infiltration in monolateral knee 5. Possibility for observation during follow-up period

Exclusion criteria

Exclusion criteria: 1. Requiring infiltration in both knees 2. BMI more than 33 3. Suffering from polyarticular disease 4. Previous knee arthroscopy within last year 5. HA or steroid intra-articular infiltration within last 3 months 6. Past history of infectious disease 7. Compromised host 8. Systemic autoimmune disease 9. Anemia with hemoglobin under 10g/dl 10. Blood disorders 11. Treatment with anticoagulant drugs (Aspirin, Warfarin) 12. Having undergone treatment with steroids during 3 months before inclusion in this study 13. Treatment with NSAIDs during 2 weeks before its inclusion in this study 14. Patients who had malignancy during 5 years before inclusion in this study 15. Patients who do not have a voluntary consent capacity 16. Patients who cannot have a consent with document 17. Patients whom the doctor has determined that it is not suitable for this clinical study

Design outcomes

Primary

Measure	Time frame
Adverse events during the treatment and follow-up period. 1. Shock 2. Pain and stiffness 3. Swelling 4. Local heat	—

Secondary

Measure	Time frame
1. The percentage of patients having a 50% decrease in the summed score for the Visual Analogue Scale from baseline to week 24. 2. Serum hyaluronic acid concentration rate before and after treatment 3. Improvement of felction and extension angle of the knee 4. Improvement rate of Japanese Knee Osteoarthritis Measure 5. Improvement of Japanese Orthopaedics Association score	—

Countries

Japan

Contacts

Public ContactTomokazu Yoshioka

University of Tsukuba Hospital Department of Rehabilitation

yoshioka@md.tsukuba.ac.jp029-853-3219

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026